Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Sona Nanotech
Deal Size : Undisclosed
Deal Type : Collaboration
BioVaxys & Sona Nanotech Enter Research Collaboration
Details : Through the collaboration, BioVaxys will leverage it's DPX Immune Educating Platform in combination with Sona’s Targeted Hyperthermia Therapy to treat solid tumors.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
May 07, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Sona Nanotech
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
Details : Under the terms of the agreement, AbCellera will lead discovery activities and AbbVie has the right to develop and commercialize therapeutic antibodies resulting from the expanded collaboration.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
January 13, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Epitopea
Deal Size : $123.5 million
Deal Type : Licensing Agreement
Epitopea and Genevant Sciences Announce Collaboration Agreement
Details : Under the agreement, Genevant granted Epitopea a global license to its LNP technology for developing RNA-based immunotherapies targeting neoplasms.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
December 19, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Epitopea
Deal Size : $123.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Congruence, Ono Collaborate on Cancer Small Molecule Correctors Development
Details : The collaboration aims to discover novel small molecule drug candidates leveraging Congruence's proprietary drug discovery platform, Revenir, for the treatment of cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $35.0 million
Deal Type : Series A Financing
Radiant Bio Raises $35M To Advance Multabody™ Therapeutic Platform
Details : This financing will enable the next stage in Radiant’s growth and move the company toward the clinic, Multabody platform against therapeutic targets that cannot be treated with traditional antibodies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 09, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $35.0 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : NanoVation Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
ME Therapeutics Begins Testing mRNA Formulations with NanoVation Therapeutics
Details : The collaboration aims to enhance the precision and efficacy of mRNA therapeutics to develop potential new cancer therapies by leveraging the cutting-edge LNP technologies of NanoVation.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : NanoVation Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Variational AI
Deal Size : Undisclosed
Deal Type : Collaboration
Rakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration
Details : The collaboration aimed at leveraging each company’s expertise to identify and develop novel small-molecule therapies against DNA-damage response targets for the treatment of cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 17, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Variational AI
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Pharma Inventor
Deal Size : Undisclosed
Deal Type : Collaboration
Rakovina Therapeutics Expands Strategic Collaborations to Support AI Research
Details : The collaboration aims to synthesize novel lead drug candidates identified by the Deep Docking AI platform for further validation, with Rakovina Therapeutics owning rights to developed molecules.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 05, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Pharma Inventor
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Charles River Laboratories, Inc
Deal Size : $18.0 million
Deal Type : Financing
Ability Biologics Closes $18 Million Seed Funding Extension for Immunomodulators
Details : The financing aims to support AI in therapeutic discovery, focusing its platform on discovering and developing potent and selective antibody therapeutics for cancer and immune-related disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Charles River Laboratories, Inc
Deal Size : $18.0 million
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Oranomed
Deal Size : Undisclosed
Deal Type : Partnership
Orano Med and 48Hour to Develop Novel Peptide Receptor Radionuclide for Targeted Cancer
Details : Partnership aims to harness the potent properties of lead-212 (212Pb), a rare alpha-emitting radioisotope, in conjunction with 48Hour Discovery’s innovative peptide discovery technology and expertise.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
June 11, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Oranomed
Deal Size : Undisclosed
Deal Type : Partnership